Caplacizumab with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura

2.1 Caplacizumab (Cablivi, Sanofi) has a marketing authorisation for treating adults and young people aged 12 years and over who weigh at least 40 kg who are 'experiencing an episode of acquired thrombotic thrombocytopenic purpura, in conjunction with plasma exchange and immunosuppression'.

2.2 The dosage schedule is available in the summary of product characteristics.

2.3 The list price of caplacizumab is £4,143 per 10‑mg vial (excluding VAT; BNF online, May 2020). The company has a commercial arrangement. This makes caplacizumab available to the NHS with a discount. The size of the discount is commercial in confidence.